Janus Henderson Group
KROS icon

Janus Henderson Group’s Keros Therapeutics KROS Stock Holding History

Janus Henderson Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-472,392
Closed -$6.31M – 2438
2025
Q2 		$6.31M Buy
+472,392
New +$6.38M ﹤0.01% 834
2025
Q1 		– Sell
-14,307
Closed -$226K – 2515
2024
Q4 		$226K Sell
14,307
-77,803
-84% -$4.04M ﹤0.01% 2380
2024
Q3 		$5.35M Buy
92,110
+77,803
+544% +$3.84M ﹤0.01% 863
2024
Q2 		$654K Buy
14,307
+4,475
+46% +$240K ﹤0.01% 1855
2024
Q1 		$649K Buy
9,832
+15
+0.2% +$889 ﹤0.01% 1873
2023
Q4 		$391K Sell
9,817
-15
-0.2% -$470 ﹤0.01% 2105
2023
Q3 		$313K Buy
9,832
+3
+0% +$112 ﹤0.01% 2162
2023
Q2 		$395K Hold
9,829
– – ﹤0.01% 2110
2023
Q1 		$420K Buy
+9,829
New +$496K ﹤0.01% 2120

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Janus Henderson Group's KROS Position: Q3 2025 in Review

Janus Henderson Group sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 472,392 shares — an estimated $6.31M sold.

Janus Henderson Group first reported a position in KROS in Q1 2023 and held it in 9 quarters. The position peaked at $6.31M in Q2 2025. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Janus Henderson Group reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Janus Henderson Group sold 472,392 Keros Therapeutics shares in Q3 2025, an estimated $6.31M.
  • Janus Henderson Group first reported a position in Keros Therapeutics in Q1 2023 and held it in 9 quarters.
  • Janus Henderson Group's Keros Therapeutics position peaked at $6.31M in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Janus Henderson Group's 13F filing for Q3 2025, filed 14 Nov 2025.